SAR-445088 is under clinical development by Sanofi and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase II drugs for Acquired (Autoimmune) Hemolytic Anemia have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SAR-445088’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-445088 (BIVV-020) is under development for the treatment of cold agglutinin disease (CAD), antibody-mediated rejection in adult kidney transplant recipients, chronic inflammatory demyelinating polyneuropathy (CIDP), polyradiculoneuropathy and idiopathic thrombocytic purpura. It is administered by the subcutaneous and intravenous route. The drug candidate is a monoclonal antibody, it acts by targeting serine protease C1s.
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
For a complete picture of SAR-445088’s drug-specific PTSR and LoA scores, buy the report here.